Moreover, the study showed a nonsignificant trend toward marginally lower critical illness and death rates in patients taking ACE inhibitors or ARBs compared to those taking other antihypertensive agents.
← all excerpts
Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19.
1
—
—